Veru’s (VERU) “Outperform” Rating Reaffirmed at Oppenheimer

Veru (NASDAQ:VERU)‘s stock had its “outperform” rating restated by Oppenheimer in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $5.00 target price on the stock.

Veru Trading Up 1.0 %

Shares of NASDAQ:VERU opened at $0.74 on Tuesday. The business has a 50 day moving average of $0.82 and a two-hundred day moving average of $0.96. Veru has a 12-month low of $0.36 and a 12-month high of $1.92. The company has a market capitalization of $108.50 million, a PE ratio of -1.54 and a beta of -0.47.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. The firm had revenue of $3.95 million during the quarter, compared to analyst estimates of $3.50 million. During the same period in the prior year, the company posted ($0.13) earnings per share. Equities research analysts predict that Veru will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Veru

Hedge funds have recently made changes to their positions in the business. Gladstone Institutional Advisory LLC grew its stake in Veru by 34.2% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock worth $44,000 after buying an additional 14,500 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of Veru by 6.1% in the second quarter. Blair William & Co. IL now owns 350,000 shares of the company’s stock valued at $294,000 after acquiring an additional 20,000 shares in the last quarter. 180 Wealth Advisors LLC raised its stake in shares of Veru by 16.6% during the 2nd quarter. 180 Wealth Advisors LLC now owns 199,100 shares of the company’s stock worth $185,000 after buying an additional 28,350 shares in the last quarter. SG Americas Securities LLC raised its position in Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after acquiring an additional 42,997 shares in the last quarter. Finally, Cetera Advisors LLC purchased a new stake in Veru during the first quarter worth about $33,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.